Sun Pharmaceutical Industries Ltd. announced its financial results for the quarter ended June 30, 2025 (Q1 FY26). The company reported a steady rise in revenue but saw a notable decline in net profit compared to the same period last year.
The company posted revenue of ₹13,851.4 crore in Q1 FY26, up 9.5% from ₹12,652.8 crore in Q1 FY25. Gross sales came in at ₹13,786.1 crore, reflecting a 10.1% rise year-on-year. However, reported net profit fell 19.6% to ₹2,278.6 crore from ₹2,835.6 crore in the same quarter last year.
Q1 FY26 Highlights:
-
India formulation sales rose 13.9% to ₹4,721.1 crore.
-
US formulation sales stood at $473 million, up 1.4% YoY.
-
Global Innovative Medicines generated $311 million in sales, a 16.9% rise, contributing 19.3% of total quarterly revenue.
-
Sales in Emerging Markets reached $298 million (up 5.1%), while Rest of World markets brought in $219 million (up 15.5%).
-
R&D investments were ₹902.9 crore, 6.5% of sales, compared to ₹794 crore in Q1 FY25.
-
EBITDA stood at ₹4,301.7 crore, up 19.2%, with an EBITDA margin of 31.1%.
-
Profit before exceptional items and tax rose 16.6% to ₹3,990.8 crore.
-
Adjusted net profit (excluding exceptional items) was ₹2,996.1 crore, up 5.7% YoY.
Dilip Shanghvi, Chairman and Managing Director of the Company, stated, “Sun had a strong performance during the quarter, where the overall growth reflects steady progress across all our markets. India continues to show strong momentum, contributing meaningfully to our performance. The U.S. launch of LEQSELVI represents an important step forward, offering a new treatment option for patients with severe alopecia areata. LEQSELVI augments our portfolio in dermatology and adds a growth engine to our Innovative Medicines business.”
